A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

To join this study, you need to be at least 18 years old and have a type of advanced or metastatic solid cancer that has been confirmed by a doctor. If your cancer has already been treated with other medicines, you might still be able to join, depending on how many treatments you've had in the past.

You'll also need to be generally well, meaning you can mostly go about your daily activities, and your body's organs (like your liver and kidneys) need to be working well. The study team will need a recent tissue sample from your cancer if one is available.

There are some reasons why you might not be able to join. For example, if you have ongoing serious side effects from previous treatments, or if you have a primary brain tumour or certain types of brain metastasis that aren't stable. Also, if you've had specific types of previous treatments or certain heart conditions, you might not be eligible. The study team will review all your medical information carefully to see if this study is right for you.

If you decide to take part in this study, the exact details of what you'll need to do, like how often you'll visit the hospital, what tests you'll have, and how long you'll be on the study drug, will depend on which part of the study you join. You'll receive the study drug, Ris-Rez, either by itself or along with other standard cancer medicines, as decided by the study doctors.

Typically, this will involve regular clinic visits for physical exams, blood tests to check your general health and how the drug is affecting you, and scans (like CT scans) to see how your cancer is responding. There will also be appointments to check for any side effects and manage them. The total time you'll be in the study will vary, but you'll have regular follow-up appointments after you stop taking the study drug to monitor your health. All these details will be fully explained before you agree to join.